デュシェンヌ型筋ジストロフィーの市場規模、シェア、成長分析、タイプ別、治療タイプ別、診断別、エンドユーザー別、地域別 - 産業予測、2025～2032年

デュシェンヌ型筋ジストロフィーの世界市場規模は2023年に21億米ドルと評価され、2024年の23億4,000万米ドルから2032年には56億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは11.6%で成長する見通しです。

世界のデュシェンヌ型筋ジストロフィー（DMD）市場は、主に男性が罹患するこの稀な遺伝性疾患に対する実行可能な治療法を発見するための研究開発が強化されるにつれて成長する見込みです。DMDは進行性の筋力低下を特徴とし、精神遅滞、呼吸不全、心臓合併症などの重篤な合併症を引き起こす可能性があります。ステロイド薬、幹細胞治療、遺伝子治療などの現在の治療法は、症状を緩和することを目的としていますが、治療法は存在しません。筋ジストロフィー協会はこの分野に多大な貢献をしており、最近ではDMD治療のための調査に7万5,000米ドルの資金を提供し、150以上のヘルスケア機関が助成金を受け取っています。遺伝子編集、エクソンスキッピング、幹細胞応用などの革新的治療への注目の高まりは、DMD治療市場をさらに前進させると予想されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• 規制分析
• 特許分析
• ケーススタディ

デュシェンヌ型筋ジストロフィー市場規模：タイプ別

• 市場概要
• デュシェンヌ型筋ジストロフィー（DMD）タイプ 1
• デュシェンヌ型筋ジストロフィー（DMD）タイプ 2
• その他

デュシェンヌ型筋ジストロフィー市場規模：治療タイプ別

• 市場概要
• 遺伝子治療
• ステロイド
• エクソンスキッピング
• 抗炎症薬
• 酵素補充療法
• その他

デュシェンヌ型筋ジストロフィー市場規模：診断別

• 市場概要
• 遺伝子検査
• 筋生検
• 筋電図検査（EMG）
• 画像診断技術（MRICTスキャン）
• 血液検査（CPK値など）

デュシェンヌ型筋ジストロフィー市場規模：エンドユーザー別

• 市場概要
• 病院
• 専門クリニック
• ホームケア
• 診断検査室

デュシェンヌ型筋ジストロフィー市場規模：投与経路別

• 市場概要
• オーラル
• 注射可能
• 話題

デュシェンヌ型筋ジストロフィー市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

デュシェンヌ型筋ジストロフィー市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer Inc.（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Mylan N.V.（US）
• Fresenius Kabi AG（Germany）
• Hikma Pharmaceuticals plc（UK）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bristol Myers Squibb Company（US）
• GSK plc（UK）
• Bayer AG（Germany）
• Sun Pharmaceutical Industries Ltd.（India）
• Boehringer Ingelheim（Germany）
• Sanofi（France）
• Sarepta Therapeutics, Inc.（US）
• Aurobindo Pharma（India）
• Capricor Therapeutics, Inc.（US）
• Catalyst Pharmaceuticals Inc（US）
• EspeRare Foundation（Switzerland）
• FibroGen, Inc.（US）
• Italfarmaco S.p.A（Italy）

結論と推奨事項

Global Duchenne Muscular Dystrophy Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.34 billion in 2024 to USD 5.64 billion by 2032, growing at a CAGR of 11.6% during the forecast period (2025-2032).

The global Duchenne muscular dystrophy (DMD) market is poised for growth as research and development efforts intensify to discover viable treatments for this rare hereditary condition, predominantly affecting males. DMD is characterized by progressive muscle weakness and can lead to serious complications such as mental retardation, respiratory failure, and heart complications. Current management approaches, including steroid medications, stem cell therapy, and gene therapy, aim to alleviate symptoms, although no cure exists. The Muscular Dystrophy Association has contributed significantly to this sector, recently funding $75,000 towards research for DMD treatments, with over 150 healthcare institutions receiving grants. Increased focus on innovative therapies such as gene editing, exon skipping, and stem cell applications is expected to further propel the DMD treatment market forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Duchenne Muscular Dystrophy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Duchenne Muscular Dystrophy Market Segmental Analysis

Global Duchenne Muscular Dystrophy Market is segmented by Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Duchenne Muscular Dystrophy (DMD) Type 1, Duchenne Muscular Dystrophy (DMD) Type 2 and Others. Based on Treatment Type, the market is segmented into Gene Therapy, Steroids, Exon Skipping, Anti-inflammatory Drugs, Enzyme Replacement Therapy and Others. Based on Diagnosis, the market is segmented into Genetic Testing, Muscle Biopsy, Electromyography (EMG), Imaging Techniques (MRI, CT scan) and Blood Tests (CPK Levels, etc.). Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Home Care and Diagnostic Laboratories. Based on Route of Administration, the market is segmented into Oral, Injectable and Topical. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Duchenne Muscular Dystrophy Market

The global Duchenne Muscular Dystrophy (DMD) market is experiencing significant growth driven by the increasing prevalence of the disorder. Key factors propelling this market include heightened awareness initiatives regarding DMD, the emergence of mutation-specific treatments, and a growing pipeline of therapeutic options. Breakthroughs such as Exondys51 and Translarna, along with corticosteroid-based anti-inflammatory therapies, further contribute to this expansion. Additionally, factors such as rising healthcare costs in developed nations and improved medical reimbursement options enhance market accessibility. The persistent unmet need for effective DMD treatments offers considerable opportunities for market players, prompting numerous companies to initiate clinical trials for innovative therapies.

Restraints in the Global Duchenne Muscular Dystrophy Market

The global Duchenne muscular dystrophy (DMD) market is expected to face significant obstacles, primarily stemming from challenges related to late diagnosis and reduced patient engagement due to prognosis uncertainties. Tracking the effectiveness of DMD treatments is complicated by the requirement for various outcome measures at different disease stages, many of which lack both sensitivity and objectivity. For instance, the widely utilized six-minute walk test can only be administered to ambulant DMD patients aged five and above, necessitating extensive cohorts and time to ascertain meaningful benefits. Moreover, the absence of appropriate outcome measures often leads to the exclusion of very young children and non-ambulant patients from clinical trials, further hindering market growth for DMD treatments.

Market Trends of the Global Duchenne Muscular Dystrophy Market

The global Duchenne muscular dystrophy (DMD) market is witnessing a significant upward trend, propelled by the emergence of innovative pharmaceuticals and disease-modifying therapies. This growth is further bolstered by substantial investments from various pharmaceutical companies dedicated to DMD research, alongside effective collaborations with patient advocacy groups that play a crucial role in fostering regulatory approval processes. As awareness and understanding of DMD enhance, the market is expected to expand, with an increased focus on personalized treatments and gene therapy advancements. This dynamic landscape indicates a promising future for stakeholders involved in DMD care and management, as they strive to address unmet medical needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Duchenne Muscular Dystrophy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Duchenne Muscular Dystrophy (DMD) Type 1
• Duchenne Muscular Dystrophy (DMD) Type 2
• Others

Global Duchenne Muscular Dystrophy Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Gene Therapy
• Steroids
• Exon Skipping
• Anti-inflammatory Drugs
• Enzyme Replacement Therapy
• Others

Global Duchenne Muscular Dystrophy Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Genetic Testing
• Muscle Biopsy
• Electromyography (EMG)
• Imaging Techniques (MRI, CT scan)
• Blood Tests (CPK Levels, etc.)

Global Duchenne Muscular Dystrophy Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Home Care
• Diagnostic Laboratories

Global Duchenne Muscular Dystrophy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical

Global Duchenne Muscular Dystrophy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Duchenne Muscular Dystrophy Market Size & CAGR (2025-2032)

• North America (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capricor Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Pharmaceuticals Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EspeRare Foundation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FibroGen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Italfarmaco S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations